Michael T. Flavin, Ph.D., Chief Executive Officer and Chairman, founded Advanced Life Sciences, Inc. in 1999. Prior to this date, he was the founder, Chief Executive Officer and Chairman of MediChem Life Sciences, Inc., a drug discovery technology and services company. Dr. Flavin took MediChem from start-up in 1987 through many stages of development including the completion of MediChemís private placement, the acquisition and integration of ThermoGen and Emerald Biostructures as MediChem subsidiaries and MediChemís initial public offering in October of 2000. MediChem was acquired in 2002 by deCODE genetics. Dr. Flavin received a B.S. in Chemistry from the University of Notre Dame, a Ph.D. in Medicinal Chemistry from the University of Illinois at Chicago and he completed a postdoctoral fellowship at Harvard University. Dr. Flavin is an Adjunct Professor for the Department of Medicinal Chemistry & Pharmacognosy at the University of Illinois at Chicago.

John L. Flavin, M.B.A., President and Director, joined us in June 2002 as Executive Vice President and Chief Financial Officer. He was elected to our board of directors in 2003 and promoted to President in 2004. Mr. Flavin was formerly the Chief Operating Officer and a director of MediChem Life Sciences, Inc. At MediChem, Mr. Flavin was responsible for developing and managing the business and scientific operations and was the Chief Executive Officer of its protein engineering and structural proteomics subsidiaries, Emerald BioStructures, ThermoGen and AXAS. Mr. Flavin holds a B.S. in Business Administration from Marquette University and an M.B.A. from Lewis University.

Suseelan Pookote, Ph.D., Executive Vice President of Corporate Development, joined us in March 2001. Prior to joining us, Dr. Pookote worked at Monsanto from 1980 to 2000, where he had responsibility for technology and business development in a variety of industry segments such as food, nutrition, biotechnology and specialty chemicals. At Monsanto, Dr. Pookote concentrated on technology evaluation, licensing and corporate transactions, including the negotiation of technology licensing deals with academic institutions. Dr. Pookote received his Ph.D. in Chemical Engineering from Northwestern University.

R. Richard Wieland II, M.B.A., Executive Vice President and Chief Financial Officer, was appointed as our Executive Vice President and Chief Financial Officer in June 2004. Prior to accepting this position, Mr. Wieland served as Chief Financial Officer of MediChem Life Sciences, Inc. where he was responsible for overseeing the financial aspects of acquiring ThermoGen and Emerald Biostructures as MediChem subsidiaries and assisting in the financial effort to complete MediChemís initial public offering. Mr. Wieland obtained his B.A. in Accounting and Economics from Monmouth College and his M.B.A. from Washington University.

Ze-Qi Xu, Ph.D., Executive Vice President and Chief Scientific Officer, joined us in 2002 from deCODE genetics, Inc., a genetics and health informatics company. Prior to deCODEís merger with MediChem Life Sciences in 2002, Dr. Xu was the Vice President of Strategic Drug Development at MediChem and oversaw the discovery, preclinical and clinical development of Calanolide A as well as the preclinical development of ALS-886 and ALS-357. Dr. Xu has published 52 articles and holds 19 patents in the fields of infectious disease and cancer. Dr. Xu earned a B.S. degree in Chemistry from Jiangxi Normal University (China), a M.S. degree in Organic Chemistry from Shanghai Medical University and a Ph.D. in Organic Chemistry from the Shanghai Institute of Organic Chemistry. He performed his postdoctoral fellowships at Clemson University and the Michigan Cancer Foundation.

David A. Eiznhamer, Ph.D., Vice President of Biological Sciences, joined us as Director of Biological Sciences in 2003 from deCODE genetics, where he was the Assistant Director of Pharmacology and ADME from January 2002 to May 2003. Dr. Eiznhamer was promoted to Vice President of Biological Sciences in May 2004. In his role at deCODE, Dr. Eiznhamer was responsible for the design and development of pharmacology and ADME research programs. Prior to that, he served as the Manager of Regulatory Affairs for MediChem Life Sciences from December 1999 to January 2002. Dr. Eiznhamer also worked as a clinical coordinator for the Division of Gastroenterology at Loyola University Medical Center in Maywood, Illinois. He has authored seven publications and made 19 presentations at national and international meetings. Dr. Eiznhamer received his Ph.D. in Molecular Biology from Loyola University of Chicago.

Patrick W. Flavin, J.D., Chief Legal Counsel, joined us in November of 2002 as legal counsel. He was promoted to Chief Legal Counsel in 2004. Prior to joining us, Mr. Flavin served as a counsel to the Illinois Speaker of the House. Prior to this position, he was the Director of Legal Affairs for MediChem Life Sciences, where he managed the in-house legal staff and outside legal counsel. Mr. Flavin obtained his B.A. from Providence College and received his J.D. from DePaul University College of Law.